ESTRO 2024 - Abstract Book

S1647

Clinical - Lung

ESTRO 2024

21. BT F, KE P. The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Annals of the New York Academy of Sciences. 2011;1217(1):45 – 59. [accessed 15 Sep 2021] Available from: https://pubmed.ncbi.nlm.nih.gov/21276005/ 22. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proceedings of the National Academy of Sciences. 2007 Feb 27;104(9):3360 – 5. [accessed 15 Sep 2021] Available from: https://www.pnas.org/content/104/9/3360 23. M L, NA G, J K, T G, MM G, F B, et al. Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer. Cancer letters. 2008 Sep 8;268(1):98 – 109. [accessed 15 Sep 2021] Available from: https://pubmed.ncbi.nlm.nih.gov/18486325/ 24. Krambeck AE, Dong H, Thompson RH, Kuntz SM, Lohse CM, Leibovich BC, et al. Survivin and B7-H1 Are Collaborative Predictors of Survival and Represent Potential Therapeutic Targets for Patients with Renal Cell Carcinoma. Clinical Cancer Research. 2007 Mar 15;13(6):1749 – 56. [accessed 15 Sep 2021] Available from: https://clincancerres.aacrjournals.org/content/13/6/1749 25. Mu C-Y, Huang J-A, Chen Y, Chen C, Zhang X-G. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. doi: 10.1007/s12032-010-9515-2

26. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nature Reviews Immunology 2008 8:6. 2008 Jun;8(6):467 – 77. [accessed 15 Sep 2021] Available from: https://www.nature.com/articles/nri2326

27. MA P, MK C, JD W. Immune Checkpoint Blockade in Cancer Therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Jun 10;33(17):1974 – 82. [accessed 15 Sep 2021] Available from: https://pubmed.ncbi.nlm.nih.gov/25605845/

28. DM P. The blockade of immune checkpoints in cancer immunotherapy. Nature reviews Cancer. 2012 Apr;12(4):252 – 64. [accessed 15 Sep 2021] Available from: https://pubmed.ncbi.nlm.nih.gov/22437870/

29. Moya-Horno I, Viteri S, Karachaliou N, Rosell R. Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC). Therapeutic Advances in Medical Oncology. 2018 Jan 1;10. [accessed 15 Sep 2021] Available from: /pmc/articles/PMC5784559/ 30. D P, T Y, MJ M, JR F, YC K, M B, et al. A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study. Clinical lung cancer. 2016 May 1;17(3):232-236.e1. [accessed 15 Sep 2021] Available from: https://pubmed.ncbi.nlm.nih.gov/27265743/ 31. GM O, C L, MK D, K Y, H A, NB L. Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer. The oncologist. 2017 Jan;22(1):70 – 80. [accessed 15 Sep 2021] Available from: https://pubmed.ncbi.nlm.nih.gov/27534573/

32. Press Releases - AstraZeneca. [accessed 15 Sep 2021] Available from: https://www.astrazeneca.com/media centre/press-releases.html